ShiraTronics, a trailblazing clinical-stage neurostimulation company, proudly presented findings from its Australian Pilot Study, RELIEV-CM, at the American Society of Pain and Neuroscience (ASPN) Pain Conference. This pioneering study showcases the world’s first fully implantable neurostimulation system specifically engineered for chronic migraine.
The RELIEV-CM Pilot Study is evaluating the preliminary safety and performance of the ShiraTronics Migraine Therapy System. The system is designed to provide a discreet, continuous solution for chronic migraine sufferers. Chronic migraine, affecting millions worldwide, is characterized by severe headaches occurring at least 15 days per month, frequently accompanied by debilitating symptoms such as nausea and light sensitivity. Current treatment options often fail to deliver consistent and lasting relief.
ShiraTronics‘ innovative system administers precise electrical pulses intended to disrupt migraine pain signals. Its unique, head-located design marks a significant departure from traditional neurostimulation systems typically intended for spinal placement. This novel approach is intended to address the mechanical and functional challenges unique to providing implantable stimulation to both the occipital and supraorbital nerves while delivering uninterrupted therapy 24 hours a day.
